BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?

BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-...

Descripción completa

Detalles Bibliográficos
Autores principales: Herr, Ricarda, Brummer, Tilman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905336/
https://www.ncbi.nlm.nih.gov/pubmed/27308494
http://dx.doi.org/10.1080/23723556.2014.1002709
_version_ 1782437249784217600
author Herr, Ricarda
Brummer, Tilman
author_facet Herr, Ricarda
Brummer, Tilman
author_sort Herr, Ricarda
collection PubMed
description BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-cell adhesion and differentiation, underlining a potential benefit of BRAF inhibitors in CRC.
format Online
Article
Text
id pubmed-4905336
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49053362016-06-15 BRAF inhibitors in colorectal cancer: Toward a differentiation therapy? Herr, Ricarda Brummer, Tilman Mol Cell Oncol Author's View BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-cell adhesion and differentiation, underlining a potential benefit of BRAF inhibitors in CRC. Taylor & Francis 2015-01-23 /pmc/articles/PMC4905336/ /pubmed/27308494 http://dx.doi.org/10.1080/23723556.2014.1002709 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Herr, Ricarda
Brummer, Tilman
BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
title BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
title_full BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
title_fullStr BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
title_full_unstemmed BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
title_short BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
title_sort braf inhibitors in colorectal cancer: toward a differentiation therapy?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905336/
https://www.ncbi.nlm.nih.gov/pubmed/27308494
http://dx.doi.org/10.1080/23723556.2014.1002709
work_keys_str_mv AT herrricarda brafinhibitorsincolorectalcancertowardadifferentiationtherapy
AT brummertilman brafinhibitorsincolorectalcancertowardadifferentiationtherapy

Ejemplares similares